New Carcinogen Found in Losartan
On February 28, 2019, the FDA recalled 87 lots of losartan after finding trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA). NMBA is the third nitrosamine found in the angiotensin II receptor blocker (ARB) medicines valsartan, losartan, and irbesartan. NDMA and NDEA, two other nitrosamines, were previously found in these drugs leading to numerous recalls.
Like NDMA and NDEA, NMBA is considered a probable human carcinogen. The FDA has concluded that the levels of NMBA found in the recalled lots are higher than the FDA’s interim acceptable intake limits. The nitrosamines found in the ARB medications can cause numerous types of cancer including liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, and multiple myeloma.
The most recent recall includes lots from Camber Pharmaceuticals, Inc. The full list of recalled products can be found on the FDA’s website. If you or a loved one took a recalled product, contact your doctor before you stop taking the product.
GoldenbergLaw is currently accepting valsartan, irbesartan, and losartan cases in which an individual was diagnosed with liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma. Contact us for a free case consultation.